Baxter Healthcare's Diazepam ANDA219882 Receives Approval Status
Baxter Healthcare Corporation's ANDA219882 for Diazepam has received an approval status of AP.
Asset / Drug
Drug and asset intelligence for Diazepam with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The FDA has accepted a supplemental application for Diazepam submitted by Hikma.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.